Based on the available data discussed, our data suggest that DPP4 inhibitors remarkably improve cognitive dysfunction in patients with T2D and decline fasting blood glucose, 2-hour postprandial blood glucose, and glycosylated hemoglobin. This evidence concerns the gene DPP4 and type 2 diabetes mellitus.